GeoVax Labs, Inc. has entered into definitive agreements to raise approximately $3.2 million through a public offering of securities, providing essential capital for advancing its clinical-stage biotechnology programs. The company will issue approximately 13.2 million units at $0.245 per unit, with each unit consisting of one share of common stock and warrants to purchase additional shares. The warrants will allow investors to purchase up to approximately 26.5 million shares at the same exercise price of $0.245 per share, exercisable immediately and valid for five years.
This financing is significant because it provides GeoVax with working capital necessary to continue developing its pipeline of immunotherapies and vaccines. As a clinical-stage biotechnology company, GeoVax requires substantial funding to advance its programs through expensive clinical trials and regulatory processes. The company's lead COVID-19 vaccine candidate, GEO-CM04S1, is currently in three Phase 2 clinical trials targeting immunocompromised patients and those for whom current vaccines are insufficient. This funding could accelerate these trials and potentially bring new treatment options to vulnerable populations more quickly.
The offering's importance extends beyond immediate financial needs, as successful development of GeoVax's technologies could address significant public health challenges. The company is also developing Gedeptin®, an oncolytic solid tumor gene-directed therapy that recently completed a Phase 1/2 clinical trial for advanced head and neck cancers. Additionally, GeoVax is advancing a vaccine targeting Mpox and smallpox, which based on recent EMA regulatory guidance may progress directly to Phase 3 clinical evaluation. These programs represent potential breakthroughs in cancer treatment and infectious disease prevention that could impact millions of patients worldwide.
Roth Capital Partners is acting as the exclusive placement agent for the offering, which is expected to close on or about December 22, 2025, subject to customary closing conditions. The shares are being offered pursuant to a registration statement on Form S-1 previously filed with the Securities and Exchange Commission. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained when available on the SEC's website at http://www.sec.gov. Investors can also access the SEC's website at www.sec.gov for additional information.
The biotechnology sector relies heavily on such capital raises to fund research and development that can take years and require significant investment before generating revenue. For investors, this offering represents an opportunity to participate in potentially transformative medical technologies, though it carries the risks inherent in clinical-stage biotech investments. The broader implication is that successful development of GeoVax's pipeline could contribute to improved healthcare outcomes, particularly for patients with limited treatment options, while potentially creating value for stakeholders who support early-stage medical innovation.
